Supernus Pharmaceuticals Reports Impressive Q1 2025 Results
Supernus Pharmaceuticals Delivers Strong Q1 2025 Financial Outcomes
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a leader in developing innovative therapies for central nervous system (CNS) disorders, has unveiled its financial results for the first quarter of 2025. The report highlights significant sales increases and encouraging advancements in their product pipeline.
Impressive Revenue Growth
In the first quarter of 2025, Supernus reported net sales of Qelbree amounting to $64.7 million, marking a remarkable 44% increase from the same quarter in 2024. Sales of GOCOVRI also saw a healthy rise, reaching $30.7 million with a 16% growth compared to the previous year. This resulted in total revenues for Q1 2025 coming in at $149.8 million, which is a 4% improvement from 2024. Notably, if Trokendi XR and Oxtellar XR are excluded from these figures, total revenues surged by 26% year over year.
Operational Performance
Despite an operating loss of $(10.3) million for the quarter, which is a decline from $(3.2) million in 2024, Supernus saw adjusted operating earnings increase by 16% to $25.9 million. This reflects the company's ability to enhance revenue generation while managing its expenses effectively. The President and CEO, Jack Khattar, shared optimism about these results, emphasizing the ongoing double-digit growth from core products and the strategic launch of ONAPGO™.
Launch of ONAPGO
April 2025 marked a significant milestone for Supernus with the launch of ONAPGO, a novel device designed for subcutaneous apomorphine infusion targeted at treating motor fluctuations in adults suffering from Parkinson’s disease. The reception from healthcare professionals has been positive, indicating strong potential for this innovative therapy to contribute to Supernus’s growth trajectory.
Commercial Highlights
During the first quarter, Qelbree prescriptions reached 214,908, an increase of 22% compared to the same quarter of the prior year. March alone saw a record number of 75,277 prescriptions written, underlining the product's expanding acceptance among prescribers. The increase in prescribers for Qelbree is notable, growing to approximately 34,416 individuals from 27,902 compared to the first quarter of last year.
Product Pipeline Developments
Supernus is not only focused on commercializing existing products but is also advancing compelling candidates in its product pipeline. SPN-817 is currently undergoing a Phase 2b double-blind study for epilepsy, targeting around 258 patients with treatment-resistant focal seizures. Additionally, the company plans to initiate a Phase 2b trial of SPN-820, aimed at treating major depressive disorder in 200 adults. This molecule represents a new approach to improving synaptic function in the brain.
Further Advancements in Pipeline
SPN-443, a novel stimulant for ADHD, has successfully concluded a Phase 1 pharmacokinetic study, showing robust bioavailability and tolerance among healthy adults. Supernus aims to announce a lead indication for SPN-443 by the end of 2025, indicating a promising future for its innovative CNS therapies.
Financial Guidance for Full Year 2025
The company has reasserted its financial guidance for the full year 2025, which anticipates total revenues of $600 - $630 million. This forecast includes approximately $65 million to $75 million expected from Trokendi XR and Oxtellar XR. Combined R&D and SG&A expenses are projected to be between $435 million and $460 million, while adjusted operating earnings are expected to fall in the range of $105 million to $130 million.
Summary of Financial Highlights
At the end of March 2025, Supernus reported total cash and marketable securities of approximately $463.6 million, a slight increase from $453.6 million at the close of 2024. This growth stems mainly from operational cash generation, slightly offset by the $25.0 million obligation linked to ONAPGO-related milestones.
Frequently Asked Questions
What are the key financial results for Q1 2025?
Supernus reported a 44% increase in Qelbree sales to $64.7 million and total revenues of $149.8 million, a 4% year-over-year growth.
What new products were launched by Supernus?
In April 2025, Supernus launched ONAPGO, a device intended for the treatment of motor fluctuations in Parkinson’s disease patients.
How has the prescriber base for Qelbree changed?
The prescriber base for Qelbree increased to approximately 34,416 in Q1 2025, up from 27,902 during the same period in the previous year.
What is Supernus's financial outlook for 2025?
The company expects total revenues between $600 - $630 million and adjusted operating earnings of $105 million to $130 million for the full year 2025.
What is included in Supernus's product pipeline?
Supernus is developing several innovative therapies including SPN-817 for epilepsy, SPN-820 for major depressive disorder, and SPN-443 for ADHD.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
